ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
ESRD can affect the pharmacokinetic disposition of drugs subject to nonrenal clearance. Cytochrome P450 (CYP) enzymes, including CYP3A, and multiple intestinal and hepatic drug transporters are thought to mediate this process, but the extent to which kidney disease alters the function of these proteins in humans is unknown. We used midazolam and fexofenadine to assess CYP3A (intestinal and hepatic) and drug transport, respectively, in patients with ESRD and healthy control subjects. We evaluated the effect of uremia on CYP3A and transporter expression in vitro by incubating normal rat hepatocytes and enterocytes with serum drawn from study participants. ESRD dramatically reduced nonrenal transporter function, evidenced by a 63% decrease in clearance (P < 0.001) and a 2.8-fold increase in area under the plasma concentration-time curve for fexofenadine (P = 0.002), compared with control subjects. We did not observe significant differences in midazolam or 1'-hydroxymidazolam clearance or area under the curve after oral administration, suggesting that CYP3A function is not changed by ESRD. Changes in hepatocyte and enterocyte protein expression in the presence of uremic serum were consistent with in vivo results. These findings demonstrate a mechanism for altered drug disposition in kidney disease, which may partially account for the high rates of drug toxicity in this population.
Nolin
Thomas D
TD
Department of Pharmacy and Therapeutics, and Center for Clinical Pharmaceutical Research, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, USA. nolin@pitt.edu
Frye
Reginald F
RF
Le
Phuong
P
Sadr
Hooman
H
Naud
Judith
J
Leblond
Francois A
FA
Pichette
Vincent
V
Himmelfarb
Jonathan
J
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology; D000328:Adult; D000368:Aged; D000818:Animals; D001806:Blood Urea Nitrogen; D051544:Cytochrome P-450 CYP3A / Q000502:physiology; D020895:Enterocytes / Q000378:metabolism; D005260:Female; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008874:Midazolam / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D008875:Middle Aged; D027361:Organic Anion Transporters / Q000502:physiology; D011446:Prospective Studies; D051381:Rats; D017207:Rats, Sprague-Dawley; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D027361:Organic Anion Transporters; D016593:Terfenadine; C040081:1-hydroxymethylmidazolam; C093230:fexofenadine; D051544:Cytochrome P-450 CYP3A; D008874:Midazolam
Drug Metab Dispos. 2006 Aug;34(8):1336-44
16698890
Pharm Res. 1999 Mar;16(3):408-14
10213372
Clin Pharmacol Ther. 2004 Oct;76(4):341-9
15470333
J Am Soc Nephrol. 2001 Feb;12(2):326-332
11158222
Pharmacogenetics. 1994 Aug;4(4):171-84
7987401
Clin Pharmacol Ther. 2000 Jul;68(1):82-91
10945319
J Pharmacol Exp Ther. 2007 Mar;320(3):978-85
17135344
Clin Pharmacol Ther. 2006 Sep;80(3):228-34
16952489
Mol Pharmacol. 2008 May;73(5):1474-83
18245269
JAMA. 2007 Nov 7;298(17):2038-47
17986697
Drug Metab Dispos. 2008 Jan;36(1):124-8
17940133
Arch Intern Med. 1999 Nov 22;159(21):2553-60
10573045
Clin Pharmacol Ther. 2007 Oct;82(4):410-26
17554244
J Am Soc Nephrol. 2006 Sep;17(9):2363-7
16899515
Br J Clin Pharmacol. 2002 May;53(5):526-34
11994059
Curr Med Res Opin. 2008 Feb;24(2):591-9
18205997
Clin Pharmacol Ther. 2006 Mar;79(3):218-30
16513446
Clin Pharmacol Ther. 2003 May;73(5):427-34
12732843
Drug Metab Dispos. 2008 Jan;36(1):61-4
17913796
Clin Pharmacol Ther. 2007 Feb;81(2):194-204
17192770
Drug Metab Dispos. 2008 Apr;36(4):663-9
18180276
Pharmacogenetics. 2003 Oct;13(10):595-606
14515058
Clin Pharmacol Ther. 1996 May;59(5):491-502
8646820
Anesthesiology. 1983 Nov;59(5):390-4
6638545
Clin Pharmacol Ther. 1998 Dec;64(6):612-21
9871426
Ann Intern Med. 1999 Mar 16;130(6):461-70
10075613
Am J Kidney Dis. 2005 Oct;46(4):669-80
16183422
N Engl J Med. 2007 Sep 27;357(13):1316-25
17898101
J Am Soc Nephrol. 2002 Jun;13(6):1579-85
12039987
Drug Metab Dispos. 2008 May;36(5):911-5
18276836
Br J Pharmacol. 2005 Apr;144(8):1067-77
15700027
Clin Pharmacol Ther. 2004 Nov;76(5):418-27
15536457
Clin Pharmacol Ther. 2002 Dec;72(6):718-28
12496753
Behav Res Methods. 2007 May;39(2):175-91
17695343
Drug Metab Dispos. 2005 Jul;33(7):963-8
15821041
Ann Pharmacother. 2005 Jul-Aug;39(7-8):1161-8
15897265
Br J Clin Pharmacol. 2005 May;59(5):602-4
15842561
Clin Pharmacol Ther. 2008 Jun;83(6):898-903
18388866
Pharmacol Ther. 2006 Jan;109(1-2):1-11
16085315
Br J Pharmacol. 2002 Dec;137(7):1039-46
12429576
Clin Pharmacol Ther. 2007 Mar;81(3):362-70
17215845
Mol Pharmacol. 2002 Jul;62(1):162-72
12065767
Clin Pharmacol Ther. 2007 Jun;81(6):828-32
17361125